Delayed Hepatitis B Vaccine at Birth Raises Infection Risks and Costs

A new analysis released in December 2025 warns that delaying the hepatitis B (HepB) birth dose vaccine for infants in the U.S. Could lead to thousands of preventable infections, hundreds of cases of liver cancer, and hundreds of millions of dollars in excess healthcare costs. The findings, published by researchers in partnership with HepVu, the Hepatitis B Foundation, and the National Viral Hepatitis Roundtable, model the consequences of postponing the vaccine from birth to later ages, such as two months or even 12 years.

Preventable Infections and Long-Term Health Risks

The study, based on a model of 2024 U.S. Births, projects that delaying the HepB birth dose to two months for infants whose mothers are not known to have hepatitis B could result in at least 1,400 preventable infections among children annually. Over time, these infections could lead to 300 excess cases of liver cancer and 480 preventable deaths each year the revised recommendation remains in place. If the vaccine is delayed until age 12, the number of preventable infections could rise to at least 2,700 per year.

Eric Hall, PhD, lead author of the study and a researcher at the Oregon Health & Science University – Portland State University School of Public Health, emphasized the critical role of timely vaccination. The hepatitis B birth dose is a critical tool for preventing infections that can last a lifetime, Hall said. When vaccination is delayed, whether by months or by years, we see predictable and preventable increases in new infections, chronic disease, liver cancer, and related deaths. These findings show how important timely protection at birth is for safeguarding children’s long-term health.

Economic Consequences of Delayed Vaccination

The financial impact of delaying the HepB birth dose is also significant. The analysis estimates that postponing the vaccine to two months could result in over $222 million in excess healthcare costs annually. If the vaccine is delayed until age 12, those costs could balloon to $313 million per year. These figures include expenses related to treating infections, managing chronic hepatitis B, and addressing long-term complications such as liver cancer.

The study’s authors argue that the birth dose is a cost-effective public health measure, preventing both immediate and long-term health burdens. The findings align with broader public health recommendations that emphasize the importance of early vaccination to reduce transmission risks, particularly in cases where maternal hepatitis B status is unknown at birth.

Public Health Implications

The analysis was conducted by a team of researchers and public health practitioners from Oregon Health & Science University, the Los Angeles County Department of Public Health, Emory University, and Cornell University. Their work underscores the importance of adhering to current vaccination schedules, which recommend the HepB vaccine be administered within 24 hours of birth for all infants, regardless of maternal hepatitis B status.

Hepatitis B is a viral infection that attacks the liver and can lead to both acute and chronic disease. Chronic hepatitis B increases the risk of liver cirrhosis and liver cancer, making early prevention a priority for public health officials. The Centers for Disease Control and Prevention (CDC) has long recommended the birth dose as a key strategy to reduce perinatal transmission, particularly in cases where maternal infection is undetected.

The study’s release comes amid broader discussions about vaccine schedules and public health policy. While the analysis does not directly address potential changes to CDC recommendations, it provides a data-driven argument for maintaining the current timeline. Public health experts have expressed concern that any delay in vaccination could undermine decades of progress in reducing hepatitis B transmission in the U.S.

Independent Validation of Vaccine Safety

The findings align with a separate independent analysis conducted by the Vaccine Integrity Project at the University of Minnesota’s Center for Infectious Disease Research and Policy (CIDRAP). Released in December 2025, the CIDRAP review examined over 400 studies and reports on the HepB vaccine and concluded that delaying the birth dose would lead to increased infections with no demonstrable benefit to vaccine safety or effectiveness. The review reinforced the existing consensus that the vaccine is both safe and critical for early protection.

Despite the strong evidence supporting the birth dose, some public health debates have centered on whether alternative vaccination timelines could reduce logistical challenges or address parental concerns. However, the new data suggests that any delay could have measurable consequences for both individual health outcomes and broader healthcare systems.

What Comes Next?

The study’s authors and public health advocates are calling for continued adherence to the current vaccination schedule, which prioritizes the HepB birth dose as a foundational component of infant immunization programs. They also emphasize the need for improved maternal screening and education to ensure that all infants receive timely protection, particularly in cases where maternal hepatitis B status is unknown.

As discussions about vaccine policy evolve, the new analysis provides a critical reminder of the stakes involved. With thousands of preventable infections and hundreds of millions of dollars in avoidable costs at risk, the debate over the HepB birth dose extends beyond individual health decisions to broader questions about public health strategy and resource allocation.

For now, the message from researchers and public health officials remains clear: timely vaccination at birth is one of the most effective tools available to protect children from hepatitis B and its long-term consequences.